Martinsried/Munich, May 2, 2012. MediGene AG (Frankfurt, Prime Standard) has obtained an additional patent for oncology drug candidate, EndoTAG®-1, from the United States Patent and Trademark Office. Patent No. 8,168,216 protects the use of EndoTAG®-1 in combination with taxanes for the treatment of triple-negative breast cancer (TNBC). This drug combination was successfully tested in a phase II clinical trial in patients with TNBC. This newly granted patent broadens the existing EndoTAG®-1 patent portfolio and has a regular term until April 2029.
About EndoTAG®-1: EndoTAG®-1 is a novel composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. The positively charged lipids imply that EndoTAG®-1 interacts with newly developed, negatively charged endothelial cells, which are primarily required for the growth of tumor blood vessels. The EndoTAG®-1 paclitaxel component attacks the endothelial cells as they divide, thus targeting the blood supply to tumors without affecting the supply to healthy tissue. By doing this, EndoTAG®-1 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth.
Medigene has successfully completed two clinical phase II trials of EndoTAG®-1 in the indications pancreatic cancer and triple-negative breast cancer (TNBC). EndoTAG®-1 has been designated orphan drug status in Europe and the USA for the treatment of pancreatic cancer. This designation has advantages for the development, approval and, under certain circumstances, the marketing of drugs.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and EndoTAG® are registered trademarks of MediGene AG. These trademarks may be owned or licensed in select locations only.
- ends -
MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene is the first German biotech company to have revenues from marketed products, which are distributed by partner companies. It has two drug candidates in clinical trials and is developing an innovative vaccine technology.
Julia Hofmann, Kerstin Langlotz
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Fax: +49 - 89 - 20 00 33 - 29 20
To unsubscribe from the press release distribution list, please go to www.medigene.com/unsubscribe.